Ainslie Derrick-Roberts

Dr. Ainslie Derrick-Roberts


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
ADAinslie Derrick-Roberts
Ainslie Derrick-Roberts
JFJanice M. Fletcher
Janice M. Fletcher
LMLynette Moore
Lynette Moore
SBSharon Byers
Sharon Byers

23 February 2017 in Diseases
Verified
Journal Article
Open access
PDF file
ADAinslie Derrick-Roberts
Ainslie Derrick-Roberts
MJMatilda Jackson
Matilda Jackson
CPCarmen E. Pyragius
Carmen E. Pyragius
SBSharon Byers
Sharon Byers
Mucopolysaccharidosis type I (MPS I) is the most common form of the MPS group of genetic diseases. MPS I results from a deficiency in the lysosomal enzyme α-l-iduronidase, leading to accumulation of undegraded heparan and dermatan sulphate glycosaminoglycan (GAG) chains in patient cells. MPS children suffer from multiple organ failure and die in their teens to early twenties. In particular, MPS I children also suffer from profound mental retardation and skeletal disease that restricts growth and movement. Neither brain nor skeletal disease is adequately treated by current therapy approaches. To overcome these barriers to effective therapy we have developed and tested a treatment called substrate deprivation therapy (SDT). MPS I knockout mice were treated with weekly intravenous injections of 1 mg/kg rhodamine B for six months to assess the efficacy of SDT. Mice were assessed using biochemistry, micro-CT and a battery of behaviour tests to determine the outcome of treatment. A reduction in female bodyweight gain was observed with the treatment as well as a decrease in lung GAG. Behavioural studies showed slight improvements in inverted grid and significant improvements in learning ability for female MPS I mice treated with rhodamine B. Skeletal disease also improved with a reduction in bone mineral volume observed. Overall, rhodamine B is safe to administer to MPS I knockout mice where it had an effect on improving aspects of neurological and skeletal disease symptoms and may therefore provide a potential therapy or adjunct therapy for MPS I patients.

1 November 2016 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
ADAinslie Derrick-Roberts
Ainslie Derrick-Roberts
KPKavita Panir
Kavita Panir
CPCarmen E. Pyragius
Carmen E. Pyragius
KZKrystyna H. Zarrinkalam
Krystyna H. Zarrinkalam
GAGerald Atkins
Gerald Atkins
SBSharon Byers
Sharon Byers

19 April 2021 in Human Gene Therapy
Verified
Journal Article
Closed access
Jennifer T SavilleJennifer T Saville
Jennifer T Saville
ADAinslie Derrick-Roberts
Ainslie Derrick-Roberts
CMChantelle McIntyre
Chantelle McIntyre
Maria FullerMaria Fuller
Maria Fuller
Mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo A syndrome) is a single gene ( SGSH ) childhood onset neurodegenerative disease for which gene therapy is in clinical trial. Theoretically, the transfer of a working gene should enable functional expression of the defective protein and rescue the phenotype when administered before the onset of irreversible disease. Recombinant adeno-associated virus (AAV) is being used as a vehicle for a number of gene therapy applications and the neurotropism of serotype 9 affords utility for monogenetic neurological disorders. To assess the efficacy of restoring the underlying biochemistry in the MPS IIIA brain, tail vein injections of self-complementary AAV9 human N -sulfoglucosamine sulfohydrolase (scAAV9.U1A.hSGSH) at 3 × 10 13 vg/kg were administered to 6- and 16-week-old MPS IIIA mice. Heparan sulfate (HS) and G M2 and G M3 gangliosides were cleared from the cortex, hippocampus and subcortex with residual storage remaining in the brain stem and cerebellum. SGSH activity increased in the brain of the MPS IIIA-treated mice, but remained significantly reduced compared with wild-type. Motor activity as assessed in an open-field arena, and gait length, improved in MPS IIIA mice treated at both 6 and 16 weeks of age. However, functional assessment of cognition in the water cross-maze test, as well as gait width, normalized in mice treated at 6 weeks of age only, with mice treated at 16 weeks performing similar to untreated MPS IIIA mice. Astrogliosis was reduced in mice treated at 6 and 16 weeks of age compared to untreated MPS IIIA mice. These results demonstrate that the gene product is actively clearing primary HS and secondary ganglioside accumulation in MPS IIIA mice, but in older mice, neurocognitive impairments remain. This is likely due to secondary downstream consequences of HS affecting neurological functions that are not reversible upon substrate clearance.

1 April 2015 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
MJMatilda Jackson
Matilda Jackson
ADAinslie Derrick-Roberts
Ainslie Derrick-Roberts
EMEllenore Martin
Ellenore Martin
NRNathan Rout-Pitt
Nathan Rout-Pitt
SGStan Gronthos
Stan Gronthos
SBSharon Byers
Sharon Byers

1 June 2016 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
XKXenia Kaidonis
Xenia Kaidonis
SBSharon Byers
Sharon Byers
EREnzo Ranieri
Enzo Ranieri
PSPeter Sharp
Peter Sharp
JFJanice Fletcher
Janice Fletcher
ADAinslie Derrick-Roberts
Ainslie Derrick-Roberts